The Equity Distribution Agreement is dated March 23, 2026. Piper Sandler's commission is 3.0% of the gross sales price per share, and the prospectus says the $4.07 share price is below net tangible book value per share.
Aardvark Therapeutics, Inc. signed an equity distribution agreement with Piper Sandler & Co. on March 23, 2026 and filed a Form S-3 shelf registration the same day. The company paused its main Phase 3 trial in February 2026 after cardiac observations in a healthy volunteer study.
The company applied to list on the Nasdaq Global Market. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are the underwriters named on the cover.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $73.8 million, plus short-term investments of $21,000, $73.9 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Aardvark Therapeutics
When did Aardvark Therapeutics go public?
Our latest story on this, dated Jan 23, 2025: "Aardvark Therapeutics files for IPO of common stock, seeks Nasdaq listing as AARD". The story links the filing or release it is based on. Read the story.
Has Aardvark Therapeutics raised money recently?
Our latest story on this, dated Mar 23, 2026: "Aardvark Therapeutics sets up $150,000,000 at-the-market stock program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Aardvark Therapeutics?
Aardvark Therapeutics, Inc. trades under the ticker AARD on NASDAQ.
Where is Aardvark Therapeutics listed?
Aardvark Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Aardvark Therapeutics?
The SEC Central Index Key (CIK) for Aardvark Therapeutics, Inc. is 1774857. Its filings are on SEC EDGAR.
How many shares does Aardvark Therapeutics have outstanding?
21,884,846 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Aardvark Therapeutics listed under?
Our directory records Aardvark Therapeutics, Inc. under United States.
What does Aardvark Therapeutics do?
Our directory classifies Aardvark Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Aardvark Therapeutics?
The ISIN recorded for Aardvark Therapeutics, Inc. is US0029421007.
Does aibio.space cover Aardvark Therapeutics?
aibio.space lists Aardvark Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Aardvark Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Aardvark Therapeutics profitable?
Aardvark Therapeutics, Inc. reported a net loss of $57.6 million for the fiscal year ended Dec 31, 2025, and used $54.2 million of cash in operations, per its annual report to the SEC.
How much does Aardvark Therapeutics spend on research and development?
$48.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Aardvark Therapeutics have?
$73.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Aardvark Therapeutics (AARD) stock news?
Our latest story on Aardvark Therapeutics, dated Apr 3, 2026: "Aardvark Therapeutics sets up $150,000,000 share sales program with Piper Sandler". The Equity Distribution Agreement is dated March 23, 2026. Piper Sandler's commission is 3.0% of the gross sales price per share, and the prospectus says the $4.07 share price is below net tangible book value per share. Source.
Investor discussion: Aardvark Therapeutics
Members talk about Aardvark Therapeutics (AARD). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Aardvark Therapeutics, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AARD on TradingView.
SEC filings and registration
SEC name
Aardvark Therapeutics, Inc.
CIK
1774857
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
AARD (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO, CA, 92122
Phone
(858) 225-7696
Shares outstanding
21,884,846 as of 2026-07-31 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Aardvark Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AARD, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio